LFA-1 expression on CD4+ CCD45RO+ peripheral blood T-lymphocytes in RR MS:: effects induced by rIFNβ-1a

被引:5
作者
Avolio, C
Ruggieri, M
Cafforio, P
Giuliani, F
Silvestris, F
Dammacco, F
Livrea, P
Trojano, M
机构
[1] Univ Foggia, Chair Neurol, Foggia, Italy
[2] Univ Bari, Dept Neurol & Psychiat Sci, Bari, Italy
[3] Univ Bari, Dept Biomed Sci & Human Oncol, Bari, Italy
关键词
LFA-1; CD4(+) CD45RO(+); peripheral blood T-lymphocytes; interferon beta-1a; soluble ICAM-1; multiple sclerosis;
D O I
10.1016/S0022-510X(01)00506-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We investigate the in vivo and in vitro effects of short-term treatment with recombinant Interferon beta-1a (rIFN beta -1a) on CD4(+)CD45RO(+) activated/memory peripheral blood T-lymphocytes (PBTLs) expressing Leukocyte Function Antigen-1 (LFA-1; CD11a/CD18) in relapsing-remitting (RR) Multiple Sclerosis (MS) patients. Blood samples were obtained from 10 RR MS patients before and after 2, 4 and 6 months of rIFN beta -1a (Avonex) treatment. For each sample, the percentage of CD4(+)CD45RO(+)CD11a(+) (CD11a(dim) and CD11a(bright)) T-cells was evaluated in in vivo PBTLs and in untreated or rIFN beta -1a (1000 U/ml) or recombinant soluble Intercellular Adhesion Molecule-1 (ICAM-1, the ligand for LFA-1) (400 ng/ml) treated cultured PBTLs by triple fluorescence flow-cytometry (FACS analysis). Soluble ICAM-1 (sICAM-1) serum levels were evaluated by ELISA. In vivo, the percentage of CD4(+) CD45RO(+), CD4(+) CD45RO(+)CD11a(+). CD4(+)CD45RO(+)CD11a(dim) PBTLs increased after 4 and 6 months of rIFN beta -1a treatment compared to pretreatment and 2 months of treatment (p < 0.05). The CD11a expression per se did not change during the time course. Soluble ICAM-1 (sICAM-1) serum levels also increased(p < 0.05) after 4 and 6 months of treatment. When T-cells, obtained from the blood of the same patients before and during in vivo treatment, were cultured either untreated or treated with rIFN beta -1a, they showed an increase in the percentage of CD4(+)CD45RO(+) T-cells expressing CD11a(bright) (p < 0.05). The addition of recombinant sICAM-1 to untreated cultures decreased the percentage of CD4(+)CD45RO(+) T-cells expressing CD11a. This last finding seems to support an indirect effect in vivo of rIFN<beta>-1a via sICAM-1 on this T-cell subset, since the ICAM-1 soluble form, induced in vivo in serum by rIFN beta -1a but lacking in in vitro conditions, keeps the percentage of CD11a(+) unchanged within CD4(+)CD45RO(+) T-cells and induces their expression of CD11a(dim), probably preventing T-cells from transmigrating. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:65 / 73
页数:9
相关论文
共 51 条
[1]  
BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003
[2]   How LFA-1 binds to different ligands [J].
Binnerts, ME ;
van Kooyk, Y .
IMMUNOLOGY TODAY, 1999, 20 (05) :240-245
[3]   Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions [J].
Bo, L ;
Peterson, JW ;
Mork, S ;
Hoffman, PA ;
Gallatin, WM ;
Ransohoff, RM ;
Trapp, BD .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (10) :1060-1072
[4]  
Budnik A, 1996, EXP HEMATOL, V24, P352
[5]   VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta [J].
Calabresi, PA ;
Pelfrey, CM ;
Tranquill, LR ;
Maloni, H ;
McFarland, HF .
NEUROLOGY, 1997, 49 (04) :1111-1116
[6]   Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b [J].
Calabresi, PA ;
Tranquill, LR ;
Dambrosia, JM ;
Stone, LA ;
Maloni, H ;
Bash, CN ;
Frank, JA ;
McFarland, HF .
ANNALS OF NEUROLOGY, 1997, 41 (05) :669-674
[7]  
CARLOS TM, 1994, BLOOD, V84, P2068
[8]   Microglial production of TNF-alpha is induced by activated T lymphocytes - Involvement of VLA-4 and inhibition by interferon beta-1b [J].
Chabot, S ;
Williams, G ;
Yong, VW .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (03) :604-612
[9]   Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study [J].
Corsini, E ;
Gelati, M ;
Dufour, A ;
Massa, G ;
Nespolo, A ;
Ciusani, E ;
Milanese, C ;
LaMantia, L ;
Salmaggi, A .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 79 (01) :76-83
[10]   ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon β-1a and TNFα [J].
Defazio, G ;
Trojano, M ;
Ribatti, D ;
Nico, B ;
Giorelli, M ;
De Salvia, R ;
Russo, G ;
Roncali, L ;
Livrea, P .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 88 (1-2) :13-20